Related Experiment Video

Updated: Aug 27, 2025

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells
09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

2.5K

Role of Receptor Interacting Protein (RIP) kinases in cancer

Kaylee Ermine1,2, Jian Yu2,3, Lin Zhang1,2

  • 1Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.

Genes & Diseases
|September 26, 2022
PubMed

Insights

Receptor Interacting Protein (RIP) kinases are crucial for cell death and survival. This review explores their dual role in cancer, offering insights into RIP kinase-targeted cancer therapies.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • The Receptor Interacting Protein (RIP) kinase family comprises seven Serine/Threonine kinases involved in cell survival and death signaling.
  • RIP1 and RIP3 are particularly known for their roles in necroptosis, a programmed necrosis and inflammatory cell death pathway.
  • Dysregulation of RIP kinases is implicated in inflammatory, neurological diseases, and cancer.

Purpose of the Study:

  • To review the multifaceted roles of RIP kinases in cancer development and progression.
  • To highlight the potential of RIP kinases as therapeutic targets in oncology.
  • To discuss opportunities for manipulating RIP kinases in cancer treatment strategies.

Main Methods:

  • Literature review of studies on RIP kinases in cancer.
  • Analysis of genetic, epigenetic, and expression alterations of RIP kinases in cancer cells.
  • Examination of clinical trial data for RIP kinase inhibitors.

Main Results:

  • RIP kinases exhibit context-dependent pro-tumor or anti-tumor functions in various cancers.
  • Alterations in RIP kinases are frequently observed in cancer, promoting tumor progression, metastasis, immune evasion, and therapeutic resistance.
  • While RIP kinase inhibitors are primarily tested for inflammatory diseases, their deregulated expression in cancer suggests therapeutic potential.

Conclusions:

  • RIP kinases represent promising, yet complex, therapeutic targets in cancer treatment.
  • Further research is needed to fully elucidate the dual roles of RIP kinases and optimize their targeting in oncology.
  • Targeting RIP kinases could offer novel strategies to overcome therapeutic resistance and enhance antitumor immunity.
Keywords:
CancerCell deathImmune responseNecroptosisRIP kinases

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K